Cancer Research UK launches a new Phase 2 clinical trial for people with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study will test the effectiveness and safety of Cytovation’s synthetic peptide therapy, CY-101 (getacatetide). The clinical development of CY-101 is part of a collaboration between Cancer Research UK, Cytovation and the Norwegian Cancer […]
Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver metastases BeOne Medicines to supply tislelizumab (a PD-1 inhibitor) for the planned Phase 2 study to be sponsored and conducted by Cytovation Bergen, Norway – May 18, 2026 – Cytovation ASA, a clinical-stage biotechnology company developing […]
Plans to initiate Phase 2 clinical trial in Adrenocortical Carcinoma in early 2026 through unique partnership between Cytovation, Cancer Research UK and the Norwegian Cancer Society Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names […]
• New funds provided largely by existing investors, led by Sandwater • Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society • New preclinical data highlighting potential of CY-101 in ACC and other cancer types driven by a dysfunctional Wnt/β-catenin pathway, including colorectal cancer, to […]
Please read press release here
February 13, 2025 03:00 ET | Source: Cytovation Brings over 30 years of life sciences industry experience Co-led the McKinsey Global Life Sciences practice Bergen, Norway, February 12, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces the appointment of Mr. Martin Dewhurst to its […]
Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinoma Cancer Research UK’s Centre for Drug Development to run the trial at sites in UK, and others across Europe The Norwegian Cancer Society to provide co-funding to support the trial LONDON, UK, and BERGEN and OSLO, Norway, 23 […]
CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of Adrenocortical Carcinoma, a Wnt/β-catenin driven tumor type Bergen, Norway, September 13, 2024 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional […]
Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today announced the election of Ellen Lubman, MBA, to its Board of Directors. “We are excited to welcome Ellen, who brings extensive experience and a well-proven track record across business […]
Findings confirm unique dual mechanism of action and fast-to-market target indication for potentially registrational trial All CICILIA trial endpoints met, with CyPep-1 demonstrating consistent safety profile across tumor types and strong early signals of efficacy. Further evidence for novel dual mechanism of action combining inhibition of Wnt/βcatenin oncogenic pathway with tumor-specific cell destruction and immune […]
